Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 152

Sort by

Sort Order Select

Journal Articles

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Nichola Cooper, MD MRCP, Isabel Gorham, BS RN, Ann M. Lowe, MD, Robert P. Numerof, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 4800.

https://doi.org/10.1182/blood-2019-126544

Published: 2019

Journal Articles

Acquired Platelet GPVI Dysfunction As Possible Predictor for Early Sepsis Diagnosis and Poor Outcome

Lukas J Weiss, Georgi Manukjan, PhD, Nils Nagler, Markus Kredel, MD, Thien-Tri Lam, MD, Bernhard Nieswandt, PhD, Dirk Weismann, MD, Harald Schulze, PhD

Blood (2019) 134 (Supplement_1): 3609.

https://doi.org/10.1182/blood-2019-131088

Published: 2019

Journal Articles

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Muhammad Zain Farooq, MD MBBS, Prasanth Lingamaneni, Saira Farid, MD, Muhammad Saad Farooq, MBBS, Ishaan Vohra, MD, Asim Tameez ud din, MD, Ankit Mangla, MBBS,MD

Blood (2019) 134 (Supplement_1): 3465.

https://doi.org/10.1182/blood-2019-132151

Published: 2019

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 3518.

https://doi.org/10.1182/blood-2019-126509

Published: 2019

Journal Articles

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Apoorva Krishna Chandar, MDMPH, Omar Ali Alaber, MD, Muhammad Zain Farooq, MD MBBS, Basma Ali Dahash, MD, Ankit Mangla, MBBS, MD

Blood (2019) 134 (Supplement_1): 4890.

https://doi.org/10.1182/blood-2019-127782

Published: 2019

Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 4889.

https://doi.org/10.1182/blood-2019-126558

Published: 2019

Journal Articles

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

William C. McManigle, MD, Rachel A. DiCioccio, BS, Sarah Anand, MD, Zhiguo Li, PhD, Jonathan C Poe, PhD, Krista R. Nichols, RN, MSN, AOCNS, Amy N. Suthers, PhD, Wei Jia, MD PhD, Kelly Corbet, BS, Megan Covington, BS, Julia Lloyd-Cowden, BS, Richard D. Lopez, MD, Gwynn D. Long, MD, Mitchell E. Horwitz, MD, Cristina Gasparetto, MD, Anthony D. Sung, MD, Nelson J. Chao, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 4521.

https://doi.org/10.1182/blood-2019-130742

Published: 2019

Journal Articles

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Jing-Ping Zhang, PhD, Qi Gao, MLS, Alexander Chan, MD, Wenbin Xiao, MD PhD, Sary El Daker, PhD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 3978.

https://doi.org/10.1182/blood-2019-130406

Published: 2019

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Gilles Salles, MD PhD, Daniel J. Landsburg, MD, Giuseppe Gritti, MD PhD, Krish Patel, MD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD, William Townsend, MRCP,MDFRCPath, Silvia Ferrari, MD, Kate F. Stumpo, BA, Shilpi Katyayan, Cheryl Li, Harry Miao, MD, Igor Proscurshim, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5310.

https://doi.org/10.1182/blood-2019-125650

Published: 2019

Journal Articles

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Adam S. Kittai, MD, Scott R Best, BS, Bria Thurlow, BSc, Basak Gokcora, Andrzej Stadnik, MPH, BS, Renee MacKinnon, Taylor Hashiguchi Rowland, BS, Daniel O. Persky, MD, Byung Park, PhD, Stephen E Spurgeon, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4295.

https://doi.org/10.1182/blood-2019-123586

Published: 2019

Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1069.

https://doi.org/10.1182/blood-2019-126473

Published: 2019

Journal Articles

Long Term Remission Achieved By Fostamatinib in ITP: A Case Report

Waleed Ghanima, MD PhD, Tjønnfjord Eirik, MD PhD

Blood (2019) 134 (Supplement_1): 4901.

https://doi.org/10.1182/blood-2019-128359

Published: 2019

Journal Articles

Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies

Teresa Sadras, PhD, Jevon Cutler, Julia Aguade-Gorgorio, PhD, Zhengshan Chen, MD PhD, Kadriye Nehir Cosgun, PhD, Akhilesh Pandey, MD PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 3922.

https://doi.org/10.1182/blood-2018-99-116954

Published: 2018

Journal Articles

Investigating Potential Mechanism(s) By Which ASO-Based Drugs Cause Thrombocytopenia

Martina H. Lundberg Slingsby, PhD, Genevieve Couldwell, Prakrith Vijey, Brooke E Terkovich, Leila Noetzli, PhD, Ross Okazaki, Jonathan N. Thon, PhD, Scott P. Henry, PhD, Padmakumar Narayanan, DVM, PhD, Joseph E. Italiano, Jr., PhD

Blood (2018) 132 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2018-99-116590

Published: 2018

Journal Articles

MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling

Manit Munshi, MS, Jiaji Chen, BS, Xia Liu, MD, Lian Xu, MS, Nickolas Tsakmaklis, BA, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Christopher Patterson, MAcc, Kirsten Meid, MPH, Joshua Gustine, MPH, Jorge J. Castillo, MD, Zachary R Hunter, PhD, Jinhua Wang, PhD, Sara J Buhrlage, PhD, Nathanael S. Gray, PhD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2018) 132 (Supplement 1): 4116.

https://doi.org/10.1182/blood-2018-99-117372

Published: 2018

Journal Articles

Resistance Mechanisms to SYK Inhibition in AML

Anjali Cremer, MD, Jana M Ellegast, MD, Yana Pikman, MD, Gabriela Alexe, PhD, Linda Ross, PhD, Amy Goodale, Federica Piccioni, PhD, Elizabeth S Frank, Thomas Oellerich, MD, Kimberly Stegmaier, MD

Blood (2018) 132 (Supplement 1): 2638.

https://doi.org/10.1182/blood-2018-99-114996

Published: 2018

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

David J. Kuter, MD DPhil, Richy Agajanian, MD, Donald M. Arnold, MD MSc, FRCPC, Michael Boxer, MD, Catherine Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Kerry A. Rogers, MD, Ann M Lowe, MD, Sandra Tong, MD, Hany Zayed, PhD, Anne-Marie Duliege, MD MS

Blood (2018) 132 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2018-99-110483

Published: 2018

Journal Articles

Dysfunctional CLEC-2 and GPVI-Mediated Signaling in Syk Y342F Knock-in Mouse Platelets

John C Kostyak, PhD, Benjamin R Mauri, BS, Carol A Dangelmaier, BS, Akruti Patel, MSc, Monica Wright, Haritha G Reddy, BS, Johannes A Eble, PhD, Satya P. Kunapuli, PhD

Blood (2018) 132 (Supplement 1): 3729.

https://doi.org/10.1182/blood-2018-99-113367

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD

Blood (2018) 132 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2018-99-113115

Published: 2018

NARROW

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Acquired Platelet GPVI Dysfunction As Possible Predictor for Early Sepsis Diagnosis and Poor Outcome

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Long Term Remission Achieved By Fostamatinib in ITP: A Case Report

Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies

Investigating Potential Mechanism(s) By Which ASO-Based Drugs Cause Thrombocytopenia

MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling

Resistance Mechanisms to SYK Inhibition in AML

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

Dysfunctional CLEC-2 and GPVI-Mediated Signaling in Syk Y342F Knock-in Mouse Platelets

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only